GSK plc completed the acquisition of efimosfermin, a specialty medicine for steatotic liver disease, for up to $2 billion, including an initial payment of $1.2 billion, on July 7, 2025. This drug aims to treat liver diseases and is expected to help address major healthcare challenges.